Potential treatment option of rivaroxaban for breastfeeding women: A case series

The use of direct oral anticoagulants (DOACs) in breastfeeding women is currently challenging due to limited safety data for breastfeeding infants, and there have been no previous studies on the drug concentration in breastfeeding infants. We treated 2 patients (one case was twin pregnancy) with venous thromboembolisms in breastfeeding women administered rivaroxaban at our institution. Blood samples from the mothers and breastmilk samples were collected at time 0 and 2  h after the rivaroxaban administration, breastfeeding was conducted 2 h after the rivaroxaban administration, and blood samples from the infants were collected 2 h after breastfeeding (4 h after maternal rivaroxaban administration).

Source: Thrombosis Research - April 4, 2024 Category: Hematology Authors: Yugo Yamashita, Daiki Hira, Makiko Morita, Yurie Katsube, Masahito Takakura, Hiroko Tomotaki, Seiichi Tomotaki, Wei Xiong, Hiroki Shiomi, Takahiro Horie, Satoshi Ueshima, Tomoyuki Mizuno, Tomohiro Terada, Koh Ono Tags: Letter to the Editors-in-Chief Source Type: research